Custom-designed lipid nanoparticles with siloxane improve cell processing for targeted mRNA therapy delivery

Competing interests: L.X. and M.J.M. are inventors on a patent filed by the Trustees of the University of Pennsylvania (International Patent Application No. PCT/US23/66564) describing the lipid nanoparticle technology in this study. J.M.W. is a paid advisor to and holds equity in iECURE, Passage Bio and the Center for Breakthrough Medicines (CBM). He also holds equity in the former G2 Bio asset companies and Ceva Santé Animale. He has sponsored research agreements with Alexion Pharmaceuticals, Amicus Therapeutics, CBM, Ceva Santé Animale, Elaaj Bio, FA212, Foundation for Angelman Syndrome Therapeutics, former G2 Bio asset companies, iECURE and Passage Bio, which are licensees of Penn Technology. J.M.W., L.W. and C.C.W are inventors on patents that have been licensed to various biopharmaceutical companies and for which they may receive payments. D.W. is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins and vaccines. M.J.M., D.W. and M.-G.A. are also named on patents describing the use of lipid nanoparticles and lipid compositions for nucleic acid delivery. The other authors declare no competing interests.